Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hemophilia A--from basic science to clinical practice.

Jens Klinge1, Natalya M Ananyeva, Charlotte A E Hauser

  • 1Hospital for Children and Adolescents, University of Erlangen, Erlangen, Germany. Jens.Klinge@kinder.imed.uni-erlangen.de

Seminars in Thrombosis and Hemostasis
|July 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cancer: A bioelectric disease?

Clinical and translational medicine·2026
Same author

Genomic landscape in Saudi patients with hepatocellular carcinoma using whole-genome sequencing: a pilot study.

Frontiers in gastroenterology (Lausanne, Switzerland)·2026
Same author

[Correction: Development of a standardized handover for critically ill premature and newborn infants for interhospital transport in Bavaria].

Zeitschrift fur Geburtshilfe und Neonatologie·2025
Same author

[Development of a standardized handover for critically ill premature and newborn infants for interhospital transport in Bavaria].

Zeitschrift fur Geburtshilfe und Neonatologie·2025
Same author

The Coral Probiotics Village: An Underwater Laboratory to Tackle the Coral Reefs Crisis.

Ecology and evolution·2025
Same author

Vascularised organoids: Recent advances and applications in cancer research.

Clinical and translational medicine·2025

This review covers advances in hemophilia A treatment, focusing on factor VIII (FVIII) replacement therapies and emerging gene therapies. It highlights improvements in FVIII concentrate safety and strategies to manage FVIII inhibitors.

Area of Science:

  • Hematology
  • Molecular Biology
  • Clinical Research

Background:

  • Hemophilia A is a common inherited bleeding disorder due to factor VIII (FVIII) deficiency.
  • Current treatments primarily involve FVIII replacement therapy, which has evolved significantly.

Purpose of the Study:

  • To summarize research advancements in hemophilia A.
  • To discuss the implementation of basic research in clinical treatment.
  • To analyze contemporary and future therapeutic strategies.

Main Methods:

  • Review of scientific literature on FVIII structure, function, and catabolism.
  • Analysis of clinical practice in hemophilia A treatment.
  • Examination of recombinant FVIII product development.
  • Summary of knowledge on FVIII inhibitors and immunotolerance induction.

Related Experiment Videos

  • Evaluation of gene-therapeutic approaches.

    • Main Results:

    • Purification and virus inactivation have improved plasma-derived FVIII concentrate safety.
    • Recombinant FVIII products offer a safer alternative, minimizing transmission risks.
    • Understanding FVIII inhibitor epitopes aids in developing strategies to overcome resistance.
    • Gene therapy presents a promising future direction for hemophilia A treatment.

    Conclusions:

    • Significant progress has been made in hemophilia A management through improved FVIII therapies.
    • Addressing FVIII inhibitors and advancing gene therapy are key priorities.
    • Continued research is crucial for developing more effective and potentially curative treatments.